, Volume 180, Issue 2, pp 191–205 | Cite as

GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon

  • Alessandro Guidotti
  • James Auta
  • John M. Davis
  • Erbo Dong
  • Dennis R. Grayson
  • Marin Veldic
  • Xianquan Zhang
  • Erminio Costa



Cortical γ-aminobutyric acid (GABA)ergic neurons contribute to the orchestration of pyramidal neuron population firing as follows: (1) by releasing GABA on GABAA and GABAB receptors, (2) by releasing reelin in the proximity of integrin receptors located on cortical pyramidal neuron dendritic spines, and (3) through reelin contributing to the regulation of dendritic spine plasticity by modulating dendritic resident mRNA translation. In schizophrenia (SZ) and bipolar (BP) postmortem brains, the downregulation of mRNAs encoding glutamic acid decarboxylase 67 (GAD67) and reelin decreases the cognate proteins coexpressed in prefrontal cortex (PFC) GABAergic neurons. This finding has been replicated in several laboratories. Such downregulation suggests that the neuropil hypoplasticity found in the PFC of SZ and BP disorder patients may depend on a downregulation of GABAergic function, which is associated with a decrease in reelin secretion from GABAergic neuron axon terminals on dendrites, somata, or axon initial segments of pyramidal neurons. Indirectly, this GABAergic neuron downregulation may play a key role in the expression of positive and negative symptoms of SZ and BP disorders.


The above described GABAergic dysfunction may be addressed by pharmacological interventions to treat SZ and BP disorders using specific benzodiazepines (BZs), which are devoid of intrinsic activity at GABAA receptors including α1 subunits but that act as full positive allosteric modulators of GABA action at GABAA receptors containing α2, α3, or α5 subunits. These drugs are expected to enhance GABAergic signal transduction without eliciting sedation, amnesia, and tolerance or dependence liabilities.

Results and conclusions

BZs, such as diazepam, although they are efficient in equilibrating GABAA receptor signal transduction in a manner beneficial in the treatment of positive and negative symptoms of SZ, may not be ideal drugs, because by mediating a full positive allosteric modulation of GABAA receptors containing the α1 subunit, they contribute to sedation and to the development of tolerance after even a brief period of treatment. In contrast, other BZ-binding site ligands, such as 6-(2bromophenyl)-8-fluoro-4H-imidazo [1,5-a][1,4] benzodiazepine-3-carboxamide (imidazenil), which fail to allosterically and positively modulate the action of GABA at GABAA receptors with α1 subunits but that selectively allosterically modulate cortical GABAA receptors containing α5 subunits, contribute to the anxiolytic, antipanic, and anticonvulsant actions of these ligands without producing sedation, amnesia, or tolerance. Strong support for the use of imidazenil in psychosis emerges from experiments with reeler mice or with methionine-treated mice, which express a pronounced reelin and GAD67 downregulation that is also operative in SZ and BP disorders. In mice that model SZ symptoms, imidazenil increases signal transduction at GABAA receptors containing α5 subunits and contributes to the reduction of behavioral deficits without producing sedation or tolerance liability. Hence, we suggest that imidazenil may be considered a prototype for a new generation of positive allosteric modulators of GABAA receptors, which, either alone or in combination with neuroleptics, should be evaluated in GABAergic dysfunction operative in the treatment of SZ and BP disorders with psychosis.


GABAA receptors Imidazenil Diazepam Psychoses Schizophrenia Bipolar disorder Reelin GABA-mimetics Benzodiazepines Glutamic acid decarboxylase 



This work is supported by RO1MH62188 to A.G., RO1MH62090 to E.C., and RO1MH6262A to D.R.G.


  1. Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M et al (2005) Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenia patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 134:60–66CrossRefPubMedGoogle Scholar
  2. Akbarian S, Huntsman MM, Kim JJ, Tafazzoli A, Potkin SG, Bunney WE Jr, Jones EG (1995a) GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cereb Cortex 6:550–560Google Scholar
  3. Akbarian S, Kim JJ, Potkin G, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG (1995b) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 552:258–266Google Scholar
  4. Auta J, Giusti P, Guidotti A, Costa E (1994) Imidazenil, a partial positive allosteric modulator of GABAA receptors, exhibits low tolerance and dependence liabilities in the rat. J Pharmacol Exp Ther 270:1262–1269PubMedGoogle Scholar
  5. Auta J, Fraust WB, Lambert P, Guidotti A, Costa E, Moerschbaecher JM (1995) Comparison of the effects of full and partial allosteric modulators of GABAA receptors on complex behavioral processes in monkeys. Behav Pharmacol 6:323–332PubMedGoogle Scholar
  6. Auta J, Guidotti A, Costa E (2000) Imidazenil prevention of alprazolam-induced acquisition in Patas monkeys is devoid of tolerance. Proc Natl Acad Sci U S A 97:2314–2319CrossRefPubMedGoogle Scholar
  7. Auta J, Costa E, Davis J, Guidotti A (2004) Imidazenil: a potent and safe protective agent against diisopropyl fluorophosphate toxicity. Neuropharmacology 46:397–403CrossRefPubMedGoogle Scholar
  8. Barnard EA (2001) The molecular architecture of GABAA receptors. In: Möhler H (ed) Handbook of experimental pharmacology, vol 150. Springer, Berlin Heidelberg New York, pp 79–99Google Scholar
  9. Benes FM (2000) Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 31:251–269CrossRefPubMedGoogle Scholar
  10. Benes FM, Berretta S (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1–27CrossRefPubMedGoogle Scholar
  11. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP (1992) Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12:924–929PubMedGoogle Scholar
  12. Benes FM, Khan Y, Vincent SL, Wickramasinghe R (1996a) Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 22:338–349CrossRefPubMedGoogle Scholar
  13. Benes FM, Vincent SL, Marie A, Khan Y (1996b) Upregulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75:1021–1031CrossRefPubMedGoogle Scholar
  14. Black JE, Kodish IM, Grossman AW, Klintsova AY, Orlovskaya D, Vostrikov V, Uranova N, Greenough WT (2004) Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry 161:742–744CrossRefPubMedGoogle Scholar
  15. Busto U, Kaplan HL, Zawertailo L, Sellers EM (1994) Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 55:451–463PubMedGoogle Scholar
  16. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237–260CrossRefPubMedGoogle Scholar
  17. Carpenter WT Jr, Buchanan RW, Kirkpatric B, Breier AF (1999) Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 156:299–303PubMedGoogle Scholar
  18. Carter CS, Botvinick MM, Cohen JD (1999) The contribution of the anterior cingulate cortex to executive processes in cognition. Rev Neurosci 10:49–57PubMedGoogle Scholar
  19. Costa E, Guidotti A (1996) Benzodiazepines on trial: a research strategy for their rehabilitation. TIPS 17:192–200PubMedGoogle Scholar
  20. Costa E, Auta J, Guidotti A (2001a) Tolerance and dependence to ligands of the benzodiazepine recognition sites expressed by GABAA receptors. In: Möhler E (ed) Handbook of experimental pharmacology, vol 150. Pharmacology of GABA and glycine neurotransmission. Springer, Berlin Heidelberg New York, pp 227–250Google Scholar
  21. Costa E, Davis J, Grayson DR, Guidotti A, Pappas GD, Pesold C (2001b) Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis 8:723–742CrossRefPubMedGoogle Scholar
  22. Costa E, Auta J, Grayson DR, Matsumoto K, Pappas DG, Zhang X, Guidotti A (2002a) GABAA receptors and benzodiazepines: a role for dendritic resident subunit mRNAs. Neuropharmacology 43:925–937CrossRefPubMedGoogle Scholar
  23. Costa E, Davis J, Pesold C, Tueting P, Guidotti A (2002b) The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr Opin Pharmacol 2:56–62CrossRefPubMedGoogle Scholar
  24. Costa E, Grayson DR, Mitchell CP, Tremolizzo L, Veldic M, Guidotti A (2003) GABAergic cortical neuron chromatin as a putative target to treat schizophrenia vulnerability. Crit Rev Neurobiol 15:121–142CrossRefPubMedGoogle Scholar
  25. Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L, Veldic M (2004) A GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit Rev Neurobiol 16:1–24CrossRefPubMedGoogle Scholar
  26. Crestani F, Löw K, Deist R, Mandelli M, Möhler H, Rudolph U (2001) Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol 59:442–445PubMedGoogle Scholar
  27. Crick FH, Koch C (2003) A framework for consciousness. Nat Neurosci 6:119–126CrossRefPubMedGoogle Scholar
  28. Cruz DA, Eggan SM, Lewis DA (2003) Postnatal development of pre- and post-synaptic GABA markers at chandelier cell inputs to pyramidal neurons in monkey prefrontal cortex. J Comp Neurol 465:385–400CrossRefPubMedGoogle Scholar
  29. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C, Opeskin K (1999) Changes in serotonin2A and GABA (A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 72:1593–1599CrossRefPubMedGoogle Scholar
  30. Dean B, Pavey G, McLeod M, Opeskin K, Keks N, Copolov D (2001) A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann’s Area 9 from subjects with bipolar disorder. J Affect Disord 66:147–158CrossRefPubMedGoogle Scholar
  31. DeFilipe J, Farinas I (1992) The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs. Prog Neurobiol 39:563–607CrossRefPubMedGoogle Scholar
  32. Delini-Stula A, Berdah-Tordjman D, Neumann N (1992) Partial benzodiazepine antagonists in schizophrenia: expectations and present clinical findings. Clin Neuropharmacol 15:405A–406APubMedGoogle Scholar
  33. Dong E, Caruncho H, Liu WS, Smalheiser NR, Grayson DR, Costa E, Guidotti A (2003) The reelin–integrin interaction regulates Arc mRNA translation in synaptoneurosomes. Proc Natl Acad Sci U S A 100:5479–5484CrossRefPubMedGoogle Scholar
  34. Eastwood SL, Harrison PJ (2003) Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. Mol Psychiatry 8:821–831CrossRefGoogle Scholar
  35. Fagiolini M, Fritschy JM, Low K, Mohler H, Rudolph U, Hensch TK (2004) Specific GABAA circuits for visual cortical plasticity. Science 303:1681–1683CrossRefPubMedGoogle Scholar
  36. Fatemi SH, Earle JA, McMenomy T (2000) Reduction in reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry 5:654–663CrossRefPubMedGoogle Scholar
  37. Fritschy JM, Möhler H (1995) GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol 359:154–194CrossRefPubMedGoogle Scholar
  38. Fritschy JM, Weinman O, Wenzel A, Benke D (1998) Synapse-specific localization of NMDA and GABA (A) receptor subunits revealed by antigen-retrieval immunohistochemistry. J Comp Neurol 390:194–210CrossRefPubMedGoogle Scholar
  39. Giusti P, Guidotti A, Danysz W, Auta J, Costa E (1990) Neuropharmacological evidence for an interaction between the GABA uptake inhibitor CI-966 and anxiolytic benzodiazepines. Drug Dev Rev 21:217–225CrossRefGoogle Scholar
  40. Giusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A, Costa E (1993) Imidazenil: a new partial positive allosteric modulator of γ-aminobutyric acid (GABA) action at GABAA receptors. J Pharmacol Exp Ther 266:1018–1028PubMedGoogle Scholar
  41. Glantz LA, Lewis DA (2001) Dendritic spine density in schizophrenia and depression. Arch Gen Psychiatry 58:203CrossRefGoogle Scholar
  42. Guidotti A, Gale K, Suria A, Toffano G (1979) Biochemical evidence for two classes of GABA receptors in rat brain. Brain Res 172:566–571CrossRefPubMedGoogle Scholar
  43. Guidotti A, Auta J, Davis JM, Dwivedi Y, Gerevini VD, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov DP, Costa E (2000) Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57:1061–1069CrossRefPubMedGoogle Scholar
  44. Halasy K, Buhl EH, Lorinczi Z, Tamas G, Somogyi P (1996) Synaptic target selectivity and input of GABAergic basket and bistratified interneurons in the CA1 area of the rat hippocampus. Hippocampus 6:306–329CrossRefPubMedGoogle Scholar
  45. Hanada S, Mita T, Nishino N (1987) [3H] muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40:259–266CrossRefPubMedGoogle Scholar
  46. Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM (2002) Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 59:521–529CrossRefPubMedGoogle Scholar
  47. Hensch TK, Stryker MP (2004) Columnar architecture sculpted by GABA circuits in developing cat visual cortex. Science 303:1619–1621CrossRefPubMedGoogle Scholar
  48. Impagnatiello F, Pesold C, Longone P, Caruncho HJ, Fritschy JM, Costa E, Guidotti A (1996) Modifications of γ aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam. Mol Pharmacol 49:822–831PubMedGoogle Scholar
  49. Impagnatiello F, Guidotti A, Pesold C, Dwivedi Y, Caruncho H, Pisu M, Uzunov D, Smalheiser N, Davis J, Pandey G, Pappas G, Tueting P, Sharma R, Costa E (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci U S A 95:15718–15723CrossRefPubMedGoogle Scholar
  50. Ishikawa M, Mizukami K, Iwakiri M, Hidaka S, Asada T (2004) Immunohistochemical and immunoblot study of GABA(A) alpha1 and beta2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Neurosci Res 50:77–84CrossRefPubMedGoogle Scholar
  51. Izzo E, Auta J, Impagnatiello F, Pesold C, Guidotti A, Costa E (2001) Glutamic acid decarboxylase and glutamate receptor changes during tolerance and dependence to benzodiazepines. Proc Natl Acad Sci U S A 98:3483–3488CrossRefPubMedGoogle Scholar
  52. Jakab RL, Goldman-Rakic PS (2000) Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 417(3):337–348CrossRefPubMedGoogle Scholar
  53. Jones EG (1993) GABAergic neurons and their role in cortical plasticity in primates. Cereb Cortex 3:361–372PubMedGoogle Scholar
  54. Jones EW (2000) Microcolumns in the cerebral cortex. Proc Natl Acad Sci U S A 97:5019–5021CrossRefPubMedGoogle Scholar
  55. Knable MB, Barci BM, Webster MJ, Woodruff JM, Torrey EF (2004) Molecular abnormalities in the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry 9:609–620CrossRefPubMedGoogle Scholar
  56. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA (2003) Neurosteroid modulation of GABAA receptors. Prog Neurobiol 71:67–80CrossRefPubMedGoogle Scholar
  57. Lees AJ, Clarke CR, Harrison MJ (1977) Hallucinations after withdrawal of baclofen. Lancet 16:858CrossRefGoogle Scholar
  58. Levitan FS, Schofield PR, Burt DR, Rhee LM, Wisden W, Kohler M, Fujita N, Rodriguez HF, Stephenson A, Darlinson MG, Barnard EA, Seeburg PH (1988) Structural and functional basis for GABAA receptor heterogeneity. Nature 335:76–79CrossRefPubMedGoogle Scholar
  59. Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325–334CrossRefPubMedGoogle Scholar
  60. Lewis DA, Volk DW, Hashimoto T (2004) Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 174:143–150CrossRefPubMedGoogle Scholar
  61. Longone P, Impagnatiello F, Guidotti A, Costa E (1996) Reversible modifications of GABAA receptor subunit mRNA expression during tolerance to diazepam-induced cognition dysfunction. Neuropharmacology 35:1465–1473CrossRefPubMedGoogle Scholar
  62. McBain CJ, Fisahn A (2001) Interneurons unbound. Nat Rev Neurosci 2:11–23CrossRefPubMedGoogle Scholar
  63. Miles R, Toth K, Gulyas AI, Hajos N, Freund GF (1996) Differences between somatic and dendritic inhibition in the hippocampus. Neuron 16:815–823CrossRefPubMedGoogle Scholar
  64. Möhler H, Crestani F, Rudolph U (2001) GABA(A)-receptor subtypes: a new pharmacology. Curr Opin Pharmacol 1:22–25CrossRefPubMedGoogle Scholar
  65. Mountcastle VB (1998) Perceptual Neuroscience. The cerebral cortex. Harvard University Press, Cambridge, MAGoogle Scholar
  66. Niu S, Renfro A, Quattrocchi CC, Sheldon M, D’Arcangelo G (2004) Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway. Neuron 41:71–84CrossRefPubMedGoogle Scholar
  67. Nusser Z, Sieghart W, Benke D, Fritschy JH, Somogyi P (1996) Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. Proc Natl Acad Sci U S A 93:11939–11944CrossRefPubMedGoogle Scholar
  68. Nyiri G, Freund TF, Somogyi P (2001) Input-dependent synaptic targeting of alpha (2)-subunit-containing GABA (A) receptors in synapses of hippocampal pyramidal cells of the rat. Eur J Neurosci 13:428–442CrossRefPubMedGoogle Scholar
  69. Perlstein WM, Carter CS, Noll DC (2001) Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenics. Am J Psychiatry 158:1105–1113CrossRefPubMedGoogle Scholar
  70. Peters A (1984) Chandelier cells. In: Jones EG, Peters A (eds) Cerebral cortex, vol 1. Plenum Press, NY, pp 361–380Google Scholar
  71. Primus RJ, Gallager DW (1992) GABA receptor subunit mRNA levels are differentially influenced by chronic FG7142 and diazepam exposure. Eur J Pharmacol 226:21–28CrossRefPubMedGoogle Scholar
  72. Rao SG, Williams GV, Goldman-Rakic PS (1999) Isodirectional tuning of adjacent interneurons and pyramidal cells during working memory: evidence for microcolumnar organization in PFC. J Neurophysiol 81:1903–1916PubMedGoogle Scholar
  73. Rao SG, Williams GV, Goldman-Rakic PS (2000) Destruction and creation of spatial tuning by disinhibition: GABAA blockade of prefrontal cortical neurons engaged by working memory. J Neurosci 20:485–494PubMedGoogle Scholar
  74. Rice DS, Curran T (2001) Role of the reelin signaling pathway in central nervous system development. Annu Rev Neurosci 24:1005–1039CrossRefPubMedGoogle Scholar
  75. Rodriguez MA, Caruncho HJ, Costa E, Pesold C, Liu WS, Guidotti A (2002) In Patas monkey GAD67 and reelin mRNA coexpression varies in a manner dependent of layer and cortical area. J Comp Neurol 451:279–288CrossRefPubMedGoogle Scholar
  76. Rosoklija G, Toomayan G, Ellis S, Keilp J, Mann JJ, Latov N, Hays AP, Andrew AJ (2000) Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 57:349–356CrossRefPubMedGoogle Scholar
  77. Sawaguchi T, Iba M (2001) Prefrontal cortical representation of visuospatial working memory in monkeys examined by local inactivation with muscimol. J Neurophysiol 86:2041–2053PubMedGoogle Scholar
  78. Sawaguchi T, Matsumura M, Kubota K (1989) Delayed response deficits produced by local injection of bicuculline into the dorsolateral prefrontal cortex in Japanese macaque monkeys. Exp Brain Res 75:457–469CrossRefPubMedGoogle Scholar
  79. Selemon LD, Goldman-Rakic PS (1999) The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45:17–25CrossRefPubMedGoogle Scholar
  80. Sieghart W (1995) Structure and pharmacology of γ-aminobutyric acidA receptor subtypes. Pharm Rev 47:181–234PubMedGoogle Scholar
  81. Skausig OB, Korsgaard S (1977) Hallucinations and baclofen. Lancet 1:158Google Scholar
  82. Soghomonian JJ, Martin DL (1998) Two isoforms of glutamate decarboxylase: why? Trends Pharmacol Sci 19:500–505CrossRefPubMedGoogle Scholar
  83. Spencer KM, Nestor PG, Perlmutter R, Niznikiewicz MA, Klump MC, Frumin M, Shenton ME, McCarley RW (2004) Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci 101:17288–17293CrossRefPubMedGoogle Scholar
  84. Stewart O, Schuman EM (2003) Compartmentalized synthesis and degradation of proteins in neurons. Neuron 9:347–359CrossRefGoogle Scholar
  85. Thompson DM, Guidotti A, Costa E (1995) Imidazenil, a new anxiolytic and anticonvulsant drug, attenuates a benzodiazepine-induced cognition deficit in monkeys. J Pharmacol Exp Ther 273:1307–1312PubMedGoogle Scholar
  86. Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P, Sharma R, Grayson DR, Costa E, Guidotti A (2002) An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci U S A 99:17095–17100CrossRefPubMedGoogle Scholar
  87. Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Pinna G, Tueting P, Rodriguez-Menendez V, Costa E, Guidotti A (2005) Valproate corrects a methionine-induced schizophrenia neuropathology in mouse. Biol Psychiatry 57:500–509CrossRefPubMedGoogle Scholar
  88. Veldic M, Caruncho H, Liu WS, Davis J, Satta R, Grayson DR, Guidotti A, Costa E (2004) DNA methyltransferase-1 (DNMT1) is selectively overexpressed in telencephalic cortical GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci U S A 101:348–353CrossRefPubMedGoogle Scholar
  89. Veldic M, Guidotti A, Maloku E, Davis JM, Costa E (2005) In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A 102:2152–2157CrossRefPubMedGoogle Scholar
  90. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA (2000) Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 57:237–245CrossRefPubMedGoogle Scholar
  91. Volk D, Austin M, Pierri J, Sampson A, Lewis D (2001) GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 158:256–265CrossRefPubMedGoogle Scholar
  92. Wassef A, Baker J, Kochan LD (2003) GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 23:601–640CrossRefPubMedGoogle Scholar
  93. Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, Herz J (2002) Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem 277:39944–39952CrossRefPubMedGoogle Scholar
  94. Williams GV, Rao SG, Goldman-Rakic PS (2002) The physiological role of 5-HT2A receptors in working memory. J Neurosci 1(22):2843–2854Google Scholar
  95. Willins DL, Deutch AY, Roth BL (1997) Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27(1):79–82CrossRefPubMedGoogle Scholar
  96. Wolkowitz DM, Pickar D (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 148:714–726PubMedGoogle Scholar
  97. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA (1998) A subclass of prefrontal γ-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A 95:5341–5346CrossRefPubMedGoogle Scholar
  98. Woo TU, Walsh JP, Benes FM (2004) Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-d-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 61:649–657CrossRefPubMedGoogle Scholar
  99. Wyatt RJ, Benedict A, Davis J (1971) Biochemical and sleep studies of schizophrenia: a review of the literature 1960–1970. Schizophr Bull 4:10–44Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Alessandro Guidotti
    • 1
  • James Auta
    • 1
  • John M. Davis
    • 1
  • Erbo Dong
    • 1
  • Dennis R. Grayson
    • 1
  • Marin Veldic
    • 1
  • Xianquan Zhang
    • 1
  • Erminio Costa
    • 1
  1. 1.Psychiatric Institute, Department of PsychiatryUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations